Hematology

But trial detects "meaningful benefit" when it comes to relapse, editorialists say

Results will likely "encourage a practice change," editorialists say

Median OS improved from 15 months to nearly 32 months with quizartinib

News, features, and commentary about cancer-related issues

Idiopathic CD4 lymphocytopenia not so heterogenous after all

Though used off-label for years, treatment isn't very beneficial

Low incidence of relapse after treatment "remarkable," researchers say

Adding polatuzumab vedotin to a modified version of R-CHOP significantly improved PFS

Research suggests cancer-specific precision monitoring and risk stratification

Overall response rate of 90% in patients who received highest doses of REGN5459

Omidubicel reduced infections in blood cancer patients from 60% to 39% at 100 days posttransplant

Dersimelagon significantly extended time to sun-related prodromal symptoms

Only difference seen was higher incidence of MRSA infection in recipients of female donor blood

Sovleplenib demonstrated "consistent response" as second-line treatment